21 July 2022  
EMA/CHMP/654924/2022  
Committee for Medicinal Products for Human Use (CHMP) 
Summary of opinion1 (post authorisation) 
Retsevmo 
selpercatinib 
On 21 July 2022, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion 
recommending a change to the terms of the marketing authorisation for the medicinal product Retsevmo. 
The marketing authorisation holder for this medicinal product is Eli Lilly Nederland B.V. 
The CHMP adopted an extension of indication for the treatment of advanced RET mutant medullary 
thyroid cancer. For information, the full indication will therefore be as follows:2  
Retsevmo as monotherapy is indicated for the treatment of adults with:  
• 
• 
advanced RET fusion positive non small cell lung cancer (NSCLC) not previously treated 
with a RET inhibitor 
advanced RET fusion positive thyroid cancer who require systemic therapy following prior 
treatment with sorafenib and/or lenvatinib 
Retsevmo as monotherapy is indicated for the treatment of adults and adolescents 12 years and 
older with advanced RET mutant medullary thyroid cancer (MTC) who require systemic therapy 
following prior treatment with cabozantinib and/or vandetanib. 
Detailed recommendations for the use of this product will be described in the updated summary of 
product characteristics (SmPC), which will be published in the revised European public assessment report 
(EPAR) and will be available in all official European Union languages after a decision on this change to the 
marketing authorisation has been granted by the European Commission. 
1 Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 
days from adoption of the opinion 
2 New text in bold, removed text as strikethrough 
Official address  Domenico Scarlattilaan 6  ●  1083 HS Amsterdam  ●  The Netherlands 
Address for visits and deliveries  Refer to www.ema.europa.eu/how-to-find-us  
Send us a question  Go to www.ema.europa.eu/contact   Telephone +31 (0)88 781 6000 
An agency of the European Union   
© European Medicines Agency, 2022. Reproduction is authorised provided the source is acknowledged. 
 
 
 
 
 
 
 
 
